Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAEMay 22, 2025 7:30 AM EDT | Source: Medicus Pharma Ltd.Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NAS ...

MONTREAL, May 22, 2025 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (“Troilus” or the “Company”, TSX: TLG; OTCQX: CHXMF; FSE: CM5R) is pleased to report additional positive drill results from the Southwest Zone (“Southwest”), at its Troilus Project located in northcentral Quebec, Canada. The results herein are part of the company’s 2025 drill campaign (outlined in the February 4, 2025 press release), focused on identifying and delineating higher-grade mineralization and enhancing confidence in the block model wit ...

May 20, 2025 IP/Design service outlook ASIC market dynamics into 2026 ◆ AWS, Google, META ASIC update AWS, Google, META ASIC update For AWS, Trainium 3 issues were solved, and it continues to book orders with downstream suppliers. After the last check of Trainium 3 test chip, we expect AWS to sign the contract of Trainium 4. Considering the new technology adoption, the actual work of Trainium 4 project has already begun. For Google, the progress on Broadcom's side has been steady from TPU v6, v7, to v8. The ...

—    Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE®, TPIP and Health Economics and Outcomes Research   —BRIDGEWATER, N.J., May 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, wh ...

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has announced the acquisition of Biolife Delaware, L.L.C., which will enhance its hemostasis product portfolio and improve patient care [1][2][5]. Company Overview - The acquisition positions MMSI to provide more standardized and simplified post-procedure care solutions [1]. - Biolife's products, StatSeal and WoundSeal, are expected to address a $350 million global market opportunity [6]. Financial Guidance - MMSI has revised its full-year 2025 financial guidance to reflect the impact of the acquisition, projecting net revenues between $1.480 billion and $1.501 billion, an increase of 9.1-10.7% compared to 2024 [10]. - The Cardiovascular segment's net revenues are now expected to be between $1.407 billion and $1.426 billion, representing an increase of 8-10% over 2024 [11]. - Adjusted EPS for 2025 is projected to be in the range of $3.28-$3.41, reflecting a decrease of 5-1% compared to 2024 [12]. Market Performance - Following the acquisition announcement, MMSI's shares gained nearly 0.7% [3]. - The company has a market capitalization of $5.81 billion and a return on equity of 15.5%, outperforming the industry average of 14.3% [4]. Industry Prospects - The global hemostasis and tissue sealing agents market is projected to grow at a CAGR of 9% from 2025 to 2030, driven by increased surgery volumes and demand for critical care [13]. - The acquisition is expected to significantly boost MMSI's business in this growing market [14].

Core Insights - Purple Biotech Ltd. presented final Phase 2 data for CM24 at the AACR Annual Meeting 2025, showing significant efficacy in biomarker subgroup analyses, which supports the patient selection strategy for the upcoming Phase 2b study planned for the second half of 2025 [4][6] - The company is advancing its pipeline with NT219, which is on track for a Phase 2 study in head and neck cancer, and the CAPTN-3 tri-specific platform is moving towards first-in-human clinical trials [2][3] Clinical Developments - CM24 demonstrated a 78% reduction in risk of death and an 81% reduction in risk of progression or death in specific biomarker subgroups [6] - NT219 will be evaluated in a Phase 2 study in combination with pembrolizumab or cetuximab for recurrent/metastatic squamous cell carcinoma of the head and neck [5][7] - New data on NT219 presented at AACR highlighted its ability to overcome immune evasion mechanisms in head and neck cancer [8] Financial Performance - Research and Development Expenses decreased by 76.5% to $0.8 million for the three months ended March 31, 2025, compared to $3.4 million in the same period of 2024 [11] - General and Administrative Expenses also decreased to $0.6 million from $1 million year-over-year [12] - The net loss for the period was $0.5 million, significantly reduced from $3.8 million in the same period of 2024, reflecting a decrease in operating expenses [15] Cash Position - As of March 31, 2025, the company had cash and cash equivalents of $6.7 million, providing a cash runway into mid-2026 [15] - The company sold approximately 63 thousand ADSs at an average price of $3.5 per ADS, generating net proceeds of approximately $166 thousand [16] Intellectual Property - A new U.S. patent for NT219 enhances global IP protection for its use in combination with EGFR antibodies, positioning the company well for future commercialization [10]

在人工智能的世界，有一群人正深耕于推动通用人工智能（AGI）从科幻走向现实。CSDN、《新程序员》特别策划 " AGI 技术 50 人 "访谈栏目 ，挖掘 AI 背后的思考，激荡 AGI 的智慧，走近那些在 AI 领域不断探索、勇于创新的思想领袖和技术先锋们的心路历程。 年初 DeepSeek 爆火，引起 X、谷歌、OpenAI、Anthropic 的顶级模型大战，随后又有 Manus 通用 Agent 问世、全世界的程序员拜入 Cursor 门下……在 2025 的 AI 炮火中，有一个名字总在提醒我们，需要时不时地从日常的喧嚣中抬起头，去思考一些更长远、也更根本的问题。 作者 | 王启隆 出品丨 《 新程序员 》编辑部 Nick Bostrom ，一位出生于瑞典，后来在牛津大学开启其重要学术生涯的哲学家。他生于 1973 年，早年似乎并不安于传统学校教育的束缚，甚至有 资料显示他高中最后一年是在家完成学业的。但这反而让他得以广泛涉猎人类学、艺术、文学乃至科学等多个领域，在伦敦求学期间还曾尝试过单口喜 剧。 2005年，Nick Bostrom 在牛津大学创办了人类未来研究所（Future of Human ...

Core Insights - Dakota Gold Corp. is advancing its Richmond Hill Heap Leach Oxide Gold Project towards an Initial Assessment with Cash Flow (IACF) expected in mid-2025 and a Feasibility Study anticipated in early 2027 [1][7] - The company has a cash balance of $47 million as of March 31, 2025, fully financing the IACF and the subsequent Feasibility Study [3] - The Maitland Gold Project is also being developed, with an initial inferred gold resource assessment expected to be completed in fall 2025 [4] Richmond Hill Project - Richmond Hill is one of the largest undeveloped oxide gold resources in the U.S. being advanced by a junior mining company [3] - The project is supported by a consultancy group and is expected to make significant progress in 2025 and into 2026 [5] - The company is currently drilling approximately 80,000 feet (24,384 meters) in 2025, focusing on metallurgical samples and resource expansion [7] Maitland Gold Project - The Maitland Gold Project is assessing exploration data from the JB Gold Zone and Unionville Zone to outline an initial inferred gold resource [4] - The JB Gold Zone has reported high-grade intersections averaging 10.76 g/t Au over 4.0 meters, while the Unionville Zone averages 4 g/t Au over 6.4 meters [4] Leadership and Corporate Structure - Recent additions to the Board and senior management include Todd Kenner, Kevin Puil, Jack Henris, and Amy Koenig, enhancing the company's leadership capacity [5] - The company emphasizes a strong safety record with no loss time incidents over the past four years [5] Feasibility Planning - Dakota Gold has engaged various consulting groups for the IACF and Feasibility Study, with M3 Engineering as the overall Study Manager [7] - The Feasibility Study is expected to be completed in 2027, focusing on a 30,000 ton per day crushing circuit [7]

这是一个来自瑞穗证券的一份研报，里面提到了对博通、英伟达、AMD、超微和华为的分析。报告 放在星球中，有兴趣的朋友可以到星球中查看原始报告。 瑞穗预计，博通定制ASIC芯片（TPUv7p/MTIA2）将在2026年加速放量，并可能在2026年下半年用 于OpenAI的Strawberry和苹果的Baltra项目。在2024年，博通的定制ASIC芯片占使用的70%-80%，绝 对的AI ASIC龙头。报告中的这个数字应该是没有考虑像Google的TPU这种自产自销的AI ASIC。 在沙特的UMAIN项目中，未来5年将部署4000台GB200 NVL72服务器（对应28万颗英伟达GPU）和 35万颗AMD GPU。在阿联酋G42项目中，承诺保证每年进口50万颗英伟达GB200 GPU（价值150亿 美元）。但笔者对这个数字持保留态度，感觉未必能持续下去。 对于超微和AMD的分析都比较简单，我们这里就不太写了。 这么看下来，今年昇腾910系列的出货量在70万以上应该是有的。 end 对华为的一个分析很有意思，报告中提到预计昇腾910在2025年订单超70万颗，下一代昇腾920将于 2026年推出。 但报告中也提到 ...

Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Urology Surgery, Pelvic Surgery), End-use, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024, and is projected to reach USD 283.8 Million by 2030, rising at a CAGR of 6.50%. The expan ...